These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
178 related articles for article (PubMed ID: 23973733)
21. Recent advances in antiviral nucleoside and nucleotide therapeutics. Simons C; Wu Q; Htar TT Curr Top Med Chem; 2005; 5(13):1191-203. PubMed ID: 16305526 [TBL] [Abstract][Full Text] [Related]
22. The search for nucleoside/nucleotide analog inhibitors of dengue virus. Chen YL; Yokokawa F; Shi PY Antiviral Res; 2015 Oct; 122():12-9. PubMed ID: 26241002 [TBL] [Abstract][Full Text] [Related]
23. Broad-spectrum antiviral activity of chebulagic acid and punicalagin against viruses that use glycosaminoglycans for entry. Lin LT; Chen TY; Lin SC; Chung CY; Lin TC; Wang GH; Anderson R; Lin CC; Richardson CD BMC Microbiol; 2013 Aug; 13():187. PubMed ID: 23924316 [TBL] [Abstract][Full Text] [Related]
24. A report from the 26th International Conference on Antiviral Research (May 11-15, San Francisco, California, USA). Rabasseda X Drugs Today (Barc); 2013 Jun; 49(6):411-7. PubMed ID: 23807944 [TBL] [Abstract][Full Text] [Related]
25. L-nucleoside enantiomers as antivirals drugs: a mini-review. Mathé C; Gosselin G Antiviral Res; 2006 Sep; 71(2-3):276-81. PubMed ID: 16797735 [TBL] [Abstract][Full Text] [Related]
29. Antivirals and antiviral strategies. De Clercq E Nat Rev Microbiol; 2004 Sep; 2(9):704-20. PubMed ID: 15372081 [TBL] [Abstract][Full Text] [Related]
30. Thiosemicarbazides: Updates on Antivirals Strategy. Moharana AK; Dash RN; Subudhi BB Mini Rev Med Chem; 2020; 20(20):2135-2152. PubMed ID: 32811412 [TBL] [Abstract][Full Text] [Related]
31. Virus-Host Interactions: New Insights and Advances in Drug Development Against Viral Pathogens. Prasad M; Ranjan K; Brar B; Shah I; Lalmbe U; Manimegalai J; Vashisht B; Gaury M; Kumar P; Khurana SK; Prasad G; Rawat J; Yadav V; Kumar S; Rao R Curr Drug Metab; 2017; 18(10):942-970. PubMed ID: 28952435 [TBL] [Abstract][Full Text] [Related]
32. Therapeutic Potential of Spirooxindoles as Antiviral Agents. Ye N; Chen H; Wold EA; Shi PY; Zhou J ACS Infect Dis; 2016 Jun; 2(6):382-92. PubMed ID: 27627626 [TBL] [Abstract][Full Text] [Related]
33. Staying ahead of viruses: a never ending task. Lamarre D; Wainberg MA Curr Opin Virol; 2012 Oct; 2(5):569-71. PubMed ID: 23025913 [No Abstract] [Full Text] [Related]
34. Antiviral drug resistance: mechanisms and clinical implications. Strasfeld L; Chou S Infect Dis Clin North Am; 2010 Jun; 24(2):413-37. PubMed ID: 20466277 [TBL] [Abstract][Full Text] [Related]
35. Highlights in antiviral drug research: antivirals at the horizon. De Clercq E Med Res Rev; 2013 Nov; 33(6):1215-48. PubMed ID: 22553111 [TBL] [Abstract][Full Text] [Related]
36. Antiviral resistance and impact on viral replication capacity: evolution of viruses under antiviral pressure occurs in three phases. Nijhuis M; van Maarseveen NM; Boucher CA Handb Exp Pharmacol; 2009; (189):299-320. PubMed ID: 19048205 [TBL] [Abstract][Full Text] [Related]
37. Resistance of hepatitis B virus to antiviral drugs: current aspects and directions for future investigation. Delaney WE; Locarnini S; Shaw T Antivir Chem Chemother; 2001 Jan; 12(1):1-35. PubMed ID: 11437320 [TBL] [Abstract][Full Text] [Related]
38. Broad-Spectrum Antivirals and Antiviral Drug Combinations. Oksenych V; Kainov DE Viruses; 2022 Feb; 14(2):. PubMed ID: 35215894 [TBL] [Abstract][Full Text] [Related]
39. Inhibitors of virus replication: recent developments and prospects. Magden J; Kääriäinen L; Ahola T Appl Microbiol Biotechnol; 2005 Mar; 66(6):612-21. PubMed ID: 15592828 [TBL] [Abstract][Full Text] [Related]
40. A comprehensive review on the antiviral activities of chalcones. Elkhalifa D; Al-Hashimi I; Al Moustafa AE; Khalil A J Drug Target; 2021 Apr; 29(4):403-419. PubMed ID: 33232192 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]